Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Distrutti, Eleonora ^a   Cipriani, Sabrina ^b   Mencarelli, Andrea ^b   Renga, Barbara ^b   Fiorucci, Stefano ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VSL3;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BDRKRB1 GENE; CCL2 GENE; CCR2 GENE; CNR1 GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HYPERALGESIA; IL 10 GENE; INFLAMMATION; IRRITABLE COLON; MALE; MATERNAL DEPRIVATION; MICROARRAY ANALYSIS; MOUSE; NOCICEPTION; NONHUMAN; NOS3 GENE; NTRK1 GENE; OPRL1 GENE; REAL TIME POLYMERASE CHAIN REACTION; THP1 GENE; TNFRSF1B GENE; TRPV4 GENE; UPREGULATION; VISCERAL PAIN; WITHDRAWAL REFLEX;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; IRRITABLE BOWEL SYNDROME; MALE; MICE; PLACEBOS; PROBIOTICS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; VISCERAL PAIN;

EID: 84877769093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063893     Document Type: Article

References (52)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, et al. (1999) Functional bowel disorders and functional abdominal pain. Gut 45: 1143-1147.
2. Mayer EA, Gebhart GF, (1994) Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107: 271-293.
3. Distrutti E, Salvioli B, Azpiroz F, Malagelada JR, (2004) Rectal function and bowel habit in irritable bowel syndrome. Am J Gastroenterol 99: 131-137.
4. De Giorgio R, Barbara G, (2008) Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol 10: 385-390.
5. Kiank C, Taché Y, Larauche M (2010) Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: Role of corticotropin-releasing factor receptors. Brain Behav Immun 1: 41-48 http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WC1-4X1SB98-1&_user=3782037&_coverDate=01%2F31%2F2010&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000061366&_version=1&_urlVersion=0&_userid=3782037&md5=9e1206c20c8fa2c8d54d2add66976cb2- implicit0.
6. Coutinho SV, Plotsky PM, Sablad M, Miller JC, Zhou H, et al. (2002) Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 282: G307-316.
7. Gareau MG, Jury J, Yang PC, MacQeen G, Perdue MH, (2006) Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance. Pediatric Research 59: 83-88.
8. Pihoker C, Owens MJ, Kuhn CM, Schanberg SM, Nemeroff CB, (1993) Maternal separation in neonatal rats elicits activation of the hypothalamic-pituitary-adrenocortical axis- a putative role for corticotropin-releasing factor. Psychoneuroendocrinology 18: 485-493.
9. Vicentic A, Francis D, Moffett M, Lakatos A, Rogge G, et al. (2006) Maternal separation alters serotonergic transporter densities and serotonergic 1A receptors in rat brain. Neuroscience 140: 355-365.
10. Ren TH, Wu J, Yew D, Ziea E, Lao L, et al. (2007) Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. American Journal of Physiology 292: G849-856.
11. Fuller R, (1989) Probiotics in man and animals. J Appl Bacteriol 66: 365-378.
12. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttilä T, Paulin L, et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 23-33.
13. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF, (2010) The probiotic Bifidobacteruium infantis 35624 displays visceral antinociceptive effects in rats. Neurogastroenterol Mot 22: 1026-e268.
14. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, et al. (2010) Effects of the probiotic bifidobacterium infantis in the maternal separation model of depression. Neuroscience 170: 1178-1189.
15. Ma X, Mao YK, Wang B, Huizinga JD, Bienenstock J, et al. (2009) Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol Gastrointest Liver Physiol 296: G868-875.
16. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors Nat Med. 13: 35-37.
17. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 8: 1103-1108.
18. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology 119: 305-309.
19. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
20. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut. 53: 108-114.
21. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546.
22. Wall GC, Schirmer LL, Anliker LE, Tigges AE, (2011) Pharmacotherapy for Acute Pouchitis. Ann Pharmacother 45: 1127-1137.
23. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895-904.
24. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, et al. (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17: 687-696.
25. Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, et al. (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51: 24-30.
26. Chung EK, Zhang X, Li Z, Zhang H, Xu H, et al. (2007) Neonatal maternal separation enhances central sensitivity to noxious colorectal distention in rat. Brain Res 1153: 68-77.
27. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, et al. (2012) VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 7(9): e45425.
28. Fiorucci S, Distrutti E, Cirino G, Wallace JL, (2006) The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 131: 259-271.
29. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, et al. (2006) 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 319: 447-458.
30. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, et al. (2006) Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther 316: 325-335.
31. Distrutti E, Mencarelli A, Renga B, Caliendo G, Santagada V, et al. (2009) A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. Pharmacol Res 5: 319-329.
32. Distrutti E, Cipriani S, Renga B, Mencarelli A, Migliorati M, et al. (2010) Hydrogen sulphide induces μ opioid receptor-dependent analgesia in a rodent model of visceral pain. Mol Pain 6: 36.
33. Al-Chaer ED, Kawasaki M, Pasricha PJ, (2000) A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 119: 1276-1285.
34. Ness TJ, Gebhart GF, (1990) Visceral pain: a review of experimental studies. Pain 41: 167-234.
35. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
36. Barrett T, Troup DB, Wilhite SE Ledoux P, Evangelista C, et al. (2011) NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 39: D1005-1010.
37. Barreau F, Ferrier L, FioramontiJ, Bueno L, (2004) Neonatal maternal deprivation triggers long term alterations in colonic ephitelial barrier and mucosal immunity in rats. GUT 53: 501-506.
38. O'Malley D, Dinan TG, Cryan JF, (2011) Neonatal maternal separation in the rat impacts on the stress responsivity of central corticotropin-releasing factor receptors in adulthood. Psychopharmacology 214: 221-229.
39. Arbolerius L, Eklund MB, (2007) Both long and brief maternal separation produces persistent changes in tissue levels of brain monoamine in middle-aged female rats. Neurosci 145: 738-750.
40. Caldji C, Francis D, Sharma S, Plotsky PM, Meaney MJ, (2000) The effects of early rearing environment on the development of GABAA and central benzodiazepine receptors levels and novelty-induced fearfulness in the rat. Neuropsychopharmacology 22: 219-229.
41. Ohtsuka Y, Ikegami T, Izumi H, Namura M, Ikeda T, et al. (2012) Effects of Bifidobacterium breve on inflammatory gene expression in neonatal and weaning rat intestine. Pediatr Res 71: 46-53.
42. Lopes LV, Marvin-Guy LF, Fuerholz A, Affolter M, Ramadan Z, et al. (2008) Maternal deprivation affects the neuromuscular protein profile of the rat colon in response to an acute stressor later in life. J Proteonomics 71: 80-88.
43. Minderhoud IM, Oldenburg B, Schipper ME, ter Linde JJ, Samsom M, (2007) Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol 75: 714-720.
44. Bian ZX, Li Z, Huang ZX, Chen HL, Xu HX, et al. (2009) Unbalanced expression of protease-activated receptors-1 and-2 in the colon of diarrhea-predominant irritable bowel syndrome patients. J Gastroenterol 44: 666-674.
45. Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM, (2010) Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 139: 249-258.
46. Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, et al. (2011) The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 141: 507-516.
47. Talwar R, Potluri VK, (2011) Cannabinoid 1 (CB1) receptor-pharmacology, role in pain and recent developments in emerging CB1 agonists. CNS Neurol Disord Drug Targets 10: 536-544.
48. Largent-Milnes TM, Vanderah TW, (2010) Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat 20: 291-305.
49. Mustazza C, Bastanzio G, (2011) Development of nociceptin receptor (NOP) agonists and antagonists. Med Rec Rev 31: 605-648.
50. Evrard B, Coudeyras S, Dosgilbert A, Charbonnel N, Alamé J, et al. (2011) Dose-dependent immunomodulation of human dendritic cells by the probiotic Lactobacillus rhamnosus Lcr35. PLoS One 6: e18735.
51. Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J, (2008) Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14: 1068-1083.
52. Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, et al. (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6: e22978.